The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Mental health services provider Lyra Health, whose earlier investors include Providence Health and Services and Castlight Health, has amassed $75m in its latest round.

Existing investor Sinopharm Capital came back for a $57.7m round that will support the progression of the small-molecule drug developer's pipeline.

Blackstone is paying an undisclosed amount for a majority share in the health plan management software provider, which raised $34m from Medica in 2017.

George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.

Bristol Myers Squibb and Otsuka Pharmaceutical were among the limited partners for what LSP said is Europe's largest ever life sciences VC fund.

Bristol-Meyers Squibb participated in the $78.5m round, which will be used to push Silverback Therapeutics' lead cancer drug candidate towards clinical trials.

The cancer immunotherapy developer has closed a $23.6m round featuring 3SBio Group and Eisai, both of which have signed collaboration agreements with it in recent months.

Optum Ventures and Heritage Provider Network reinvested as the healthcare expertise platform increased its overall funding to $40m with a series C round led by Deerfield Managment.

The ultrasound surgery system developer is targeting $150m at a $1.3bn post-money valuation, with Koch Disruptive Technologies supplying $100m.